Information Provided By: 
Fly News Breaks for March 26, 2015
GWPH
Mar 26, 2015 | 08:30 EDT
Leerink says the risk/reward on shares of GW Pharmaceuticals is favorable into the Epidiolex update at AAN on April 22 despite the 34% rally since the last update in October. The firm notes its price target of $102 assumes a 66% probability-of-success for Epidiolex in Dravet/Lennox Gastaut. Changing the probabilities to 100% yields a target of $182, Leerink notes. It reiterates an Outperform rating on GW.
News For GWPH From the Last 2 Days
There are no results for your query GWPH
